TriangleNCT02798536 · OUTCOME
Median Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- At progression, up to 3.6 months
What was measured
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.
Groups in this outcome
Dose Level 1: 170mcg LMB-100
Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.
Dose Level -1: 140mcg LMB-100
Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.
Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel
Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.
| Group | Source count |
|---|---|
| Dose Level 1: 170mcg LMB-100 | 3 |
| Dose Level -1: 140mcg LMB-100 | 7 |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | 11 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Level 1: 170mcg LMB-100 | 2.7 | Not reported | 2.7 | 3.0 | Not reported |
| Dose Level -1: 140mcg LMB-100 | 2.7 | Not reported | 1.5 | 3.2 | Not reported |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | 2.7 | Not reported | 1.3 | 3.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.7
- upper Limit
- 3.0
- value
- 2.7
- group Id
- OG001
- lower Limit
- 1.5
- upper Limit
- 3.2
- value
- 2.7
- group Id
- OG002
- lower Limit
- 1.3
- upper Limit
- 3.6
- value
- 2.7
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 11
- units
- Participants
- description
- PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.
- id
- OG000
- title
- Dose Level 1: 170mcg LMB-100
- description
- Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.
- id
- OG001
- title
- Dose Level -1: 140mcg LMB-100
- description
- Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.
- id
- OG002
- title
- Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- At progression, up to 3.6 months
- title
- Median Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice